Fresenius Medical Care (FMS) is considered undervalued with a price-to-earnings ratio below 10 despite expected annual earnings growth of 7-9%. The company has improved its fundamentals by expanding margins by 300-400 basis points, achieving over €800 million in savings, and reducing leverage to 2.5 times, enhancing its investment-grade profile. Even with flat or low growth, FMS offers a potential 40-60% upside to a $29 per share target price, justifying a 'Buy' rating. Risks such as reimbursement changes, inflation, and US political factors are manageable due to FMS's market leadership and strong cost controls.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
